$18.3 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$75.52 - $110.37The lowest and highst price in the last 52 weeks.
38.21xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$18.3 Billion|
|Enterprise Value||$16.4 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-13.7%|
|Outstanding Shares||220 Million|
|Avg 30 Day Volume||1.17 Million|
|Earnings per Share||$2.18|
|Price to Sales Ratio||7.0|
|Price to Book Ratio||7.0|
|Revenue to Enterprise Value||6.05|
|EBIT to Enterprise Value||28.56|
|Total Debt to Enterprise Value||0.0|
|Debt to Equity||0.01|
|Gross Profit||$2.57 Billion|
|Net Income||$478 Million|
|Quarterly Earnings Growth (YoY)||-107.4%|
|Return on Equity||17.54%|
|Return on Assets||13.07%|
|Return on Invested Capital||18.85%|
Incyte (NASDAQ:INCY) posted its quarterly earnings results on Monday. The biopharmaceutical company reported $0.93 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.63 by $...Transcript Daily, 4 months ago
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Fourth Quarter and Year-End Financial Results, Provides 2021 Financial Guidance and Updates on Key Clinical ProgramsBusiness Wire, 4 months ago
Mizuho Securities Stick to Their Hold Rating for Incyte CorpInvesting.com, 5 months ago